Danuta Marona-Lewicka
Overview
Explore the profile of Danuta Marona-Lewicka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
314
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin D, Marona-Lewicka D, Nichols D, Nichols C
Neuropharmacology
. 2014 Apr;
83:1-8.
PMID: 24704148
Chronic administration of lysergic acid diethylamide (LSD) every other day to rats results in a variety of abnormal behaviors. These build over the 90 day course of treatment and can...
2.
Juncosa Jr J, Hansen M, Bonner L, Cueva J, Maglathlin R, McCorvy J, et al.
ACS Chem Neurosci
. 2013 Jan;
4(1):96-109.
PMID: 23336049
Based on the structure of the superpotent 5-HT(2A) agonist 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, which consists of a ring-substituted phenethylamine skeleton modified with an N-benzyl group, we designed and synthesized a small library of...
3.
Marona-Lewicka D, Nichols D
Behav Pharmacol
. 2011 Aug;
22(5-6):508-15.
PMID: 21814134
Activation of the dopaminergic system underlies the behavioral effects of (+)-amphetamine, and plays a major role in its discriminative stimulus properties. Although serotonin receptors modulate dopamine levels in the brain,...
4.
Marona-Lewicka D, Nichols C, Nichols D
Neuropharmacology
. 2011 Mar;
61(3):503-12.
PMID: 21352832
Many people who take LSD experience a second temporal phase of LSD intoxication that is qualitatively different, and was described by Daniel Freedman as "clearly a paranoid state." We have...
5.
Marona-Lewicka D, Nichols D
Behav Pharmacol
. 2009 Jan;
20(1):114-8.
PMID: 19179855
In-vitro studies have shown that WAY 100635 is not only a potent 5-HT1A antagonist, but also has high affinity and efficacy at the dopamine D(4) receptor. Nevertheless, the behavioral effects...
6.
Marona-Lewicka D, Chemel B, Nichols D
Psychopharmacology (Berl)
. 2008 Jul;
203(2):265-77.
PMID: 18604600
Rationale: Lysergic acid diethylamide (LSD) differs from other types of hallucinogens in that it possesses direct dopaminergic effects. The exact nature of this component has not been elucidated. Objective: The...
7.
Schultz D, Prescher J, Kidd S, Marona-Lewicka D, Nichols D, Monte A
Bioorg Med Chem
. 2008 May;
16(11):6242-51.
PMID: 18467103
Phenylalkylamines that possess conformationally rigidified furanyl moieties in place of alkoxy arene ring substituents have been shown previously to possess the highest affinities and agonist functional potencies at the serotonin...
8.
Marona-Lewicka D, Nichols D
Pharmacol Biochem Behav
. 2007 Jul;
87(4):453-61.
PMID: 17618679
Activation of 5-HT(2A) receptors is thought to mediate the hallucinogenic effects of LSD. Nevertheless, in a previous report we provided evidence that a delayed temporal phase of the behavioral pharmacology...
9.
McLean T, Parrish J, Braden M, Marona-Lewicka D, Gallardo-Godoy A, Nichols D
J Med Chem
. 2006 Sep;
49(19):5794-803.
PMID: 16970404
A series of conformationally restricted analogues of the hallucinogenic phenethylamine 1 (2,5-dimethoxy-4-bromophenethylamine, 2C-B) was synthesized to test several hypotheses concerning the bioactive conformation of phenethylamine ligands upon binding to the...
10.
McLean T, Chambers J, Parrish J, Braden M, Marona-Lewicka D, Kurrasch-Orbaugh D, et al.
J Med Chem
. 2006 Jul;
49(14):4269-74.
PMID: 16821786
A conformationally restricted analogue of mescaline, C-(4,5,6-trimethoxyindan-1-yl)-methanamine, was designed using a 5-HT(2A) receptor homology model. The compound possessed 3-fold higher affinity and potency than and efficacy equal to that of...